Home › Compare › PAIOF vs JEPQ

PAIOF vs JEPQ: Dividend Comparison 2026

PAIOF yields 20000.00% · JEPQ yields 11.47%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PAIOF wins by $52481917574412746752.00M in total portfolio value
10 years
PAIOF
PAIOF
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full PAIOF calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.47%
Share price
$53.77
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.8K
Annual income
$2,269.18
Full JEPQ calculator →

Portfolio growth — PAIOF vs JEPQ

📍 PAIOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPAIOFJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PAIOF + JEPQ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PAIOF pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PAIOF
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
JEPQ
Annual income on $10K today (after 15% tax)
$974.55/yr
After 10yr DRIP, annual income (after tax)
$1,928.80/yr
At 15% tax rate, PAIOF beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PAIOF + JEPQ for your $10,000?

PAIOF: 50%JEPQ: 50%
100% JEPQ50/50100% PAIOF
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PAIOF buys
0
JEPQ buys
0
No recent congressional trades found for PAIOF or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPAIOFJEPQ
Forward yield20000.00% ✓11.47%
Annual dividend / share$2.00$6.16 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$52481917574412746752.00M ✓$45.8K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00 ✓$2,269.18
Total dividends collected$52448189483771600896.00M ✓$17.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: PAIOF vs JEPQ ($10,000, DRIP)

YearPAIOF PortfolioPAIOF Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$2,010,700$2,000,000.00$11,967$1,146.53+$2.00M → PAIOF
2$377,983,225$375,831,775.70$14,216$1,268.02+$377.97M → PAIOF
3$66,433,479,469$66,029,037,418.28$16,774$1,392.20+$66433.46M → PAIOF
4$10,916,985,471,987$10,845,901,648,955.73$19,667$1,518.21+$10916985.45M → PAIOF
5$1,677,384,363,769,318$1,665,703,189,314,291.80$22,925$1,645.21+$1677384363.75M → PAIOF
6$240,985,175,079,139,100$239,190,373,809,905,920.00$26,578$1,772.40+$240985175079.11M → PAIOF
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$30,656$1,899.04+$32373573631143.66M → PAIOF
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$35,194$2,024.45+$4066766648320630.00M → PAIOF
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$40,228$2,148.01+$477730483406513344.00M → PAIOF
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$45,796$2,269.18+$52481917574412746752.00M → PAIOF

PAIOF vs JEPQ: Complete Analysis 2026

PAIOF — Stock

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.

Full PAIOF Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this PAIOF vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PAIOF vs SCHDPAIOF vs JEPIPAIOF vs OPAIOF vs KOPAIOF vs MAINPAIOF vs XYLDPAIOF vs QYLDPAIOF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.